GlassScriptPhysician profile
Brian W Gebhart
NPI 1487695896
$2,632.99
in general payments reported to CMS, 2019-2025
14 companies · $80.46 in 2025
The $80.46 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $330 · 2020: $85.48 · 2022: $99.62 · 2023: $342 · 2024: $1,695 · 2025: $80.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,170 · Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,169.93 |
| Food and Beverage | $947.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $1,953.05 | 2019-2024 | Phasix Mesh |
| Intuitive Surgical, INC. | $173.36 | 2019 | |
| Cook Biotech Incorporated | $110.65 | 2023 | Biodesign |
| Ethicon US, LLC | $96.82 | 2020-2024 | Dermabond, Enseal X1 |
| Smith+Nephew, INC. | $88.46 | 2024-2025 | Stravix Pl, Grafix Pl |
| Karl Storz Endoscopy-America | $44.80 | 2019-2020 | |
| Tei Biosciences INC | $36.27 | 2019 | |
| Organogenesis INC. | $30.04 | 2023 | Puraply |
| Integra Lifesciences Corporation | $19.91 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Merck Sharp & Dohme LLC | $19.31 | 2019 | |
| Myriad Genetic Laboratories, INC. | $18.43 | 2023 | Myrisk |
| Csl Behring | $14.90 | 2019 | |
| Shire North American Group INC | $13.71 | 2019 | |
| Biocomposites INC | $13.28 | 2025 | Stimulan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gebhart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.